Comparative Pharmacology
Head-to-head clinical analysis: EKTERLY versus IDVYNSO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EKTERLY versus IDVYNSO.
EKTERLY vs IDVYNSO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ekterly is a tissue-selective estrogen receptor degrader (SERD) that binds to the estrogen receptor (ER) and induces conformational changes leading to ER degradation. It antagonizes ER-mediated gene transcription and signaling, thereby inhibiting ER-dependent breast cancer cell proliferation.
IDVYNSO is a selective dopamine D3 receptor antagonist, which modulates dopaminergic neurotransmission in the mesolimbic pathway.
10 mg orally once daily
5 mg/kg IV once daily for 14 days; then 2.5 mg/kg IV once daily for 14 days.
None Documented
None Documented
Terminal elimination half-life is 12 hours. Steady state reached within 2 days. Accumulation negligible with once-daily dosing.
Terminal elimination half-life is 12–18 hours, supporting twice-daily dosing in patients with normal renal function.
Renal excretion accounts for 70% of elimination, with 30% hepatobiliary/fecal. Approximately 15% is excreted unchanged in urine; the remainder as glucuronide metabolites.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%, with the remainder metabolized.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent